Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(40.0%)
Phase 2
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 4(2)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04690283Phase 3Unknown

Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

Role: lead

NCT02520219Phase 2Unknown

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Role: lead

NCT02513355Phase 4Unknown

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Role: lead

NCT02510118Phase 2Unknown

Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

Role: lead

NCT02513342Phase 4Unknown

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Role: lead

All 5 trials loaded